car-t gives sustained disease control in r/r adult dlbcl: updated juliet analysis
Published 5 years ago • 81 plays • Length 4:27Download video MP4
Download video MP3
Similar videos
-
2:25
juliet: crs and neurotoxicity in dlbcl
-
2:38
car t-cells improve response and cr rates in r/r dlbcl
-
3:05
car-t therapy in r/r dlbcl
-
3:27
using ai to predict patient response to car-t cell therapy: analysis of the juliet trial
-
1:33
patient selection for car-t in all
-
1:49
a novel subcutaneous car-t therapy for the treatment of hematological malignancies
-
11:18
car-t cells: engineered cancer killers
-
29:50
episode 34 – travis young: finding a cure for cancer with novel immunotherapies
-
1:01:36
deciphering car-t cells: exploring functional mechanisms to drive next generation immunotherapy
-
1:00
car t studies with significantly delayed onset of gvhd
-
1:43
management of car-t related side effects
-
21:31
what's new in car-t?
-
3:08
current car-t treatments for t-all and next steps
-
1:39
exploring the applications of car-ts beyond hematology and oncology
-
3:04
applying molecular understanding of dlbcl to management strategies
-
1:16
car-t treatment journey and the role of the nurse
-
2:30
car-t as a new standard of care in lymphoma
-
3:28
management of relapse after car-t
-
0:52
nursing and car-t therapy
-
0:42
targeted therapies for dlbcl treatment
-
1:12
novel all treatment strategies: car t-cells
-
2:26
clinical data for cd19-directed car t-cell products in all